Skip to main content

Table 1 Comparison between the two studied groups according to baseline patient characteristics

From: Intermittent fasting during adjuvant chemotherapy may promote differential stress resistance in breast cancer patients

 

Intermittent fasting

(n = 24)

Non-fasting (n = 24)

P

Age (years)

 Mean ± SD

43.96 ± 7.37

47.42 ± 11.73

0.229

 Median (min.–max.)

44.0 (30.0–60.0)

45.0 (27.0–66.0)

Weight (kg)

   

 Mean ± SD

88.83 ± 14.14

87.83 ± 17.40

0.828

 Median (min.–max.)

86.0 (65.0–113.0)

86.50 (49.0–130.0)

Height (m)

 Mean ± SD

1.67 ± 0.05

1.66 ± 0.05

0.330

 Median (min.–max.)

1.68 (1.55–1.75)

1.66 (1.50–1.72)

BMI (kg/m2)

 Mean ± SD

31.77 ± 4.06

31.89 ± 5.35

0.933

 Median (min.–max.)

32.23 (23.88–36.96)

32.33 (21.67–43.94)

ER

No. %

No. %

MCp = 0.462

 Negative

6 (25.0%)

4 (16.7%)

 1 + 

0 (0.0%)

1 (4.2%)

 2 + 

8 (33.3%)

5 (20.8%)

 3 + 

10 (41.7%)

14 (58.3%)

PR

 Negative

7 (29.2%)

4 (16.7%)

MCp = 0.595

 1 + 

3 (12.5%)

3 (12.5%)

 2 + 

3 (12.5%)

6 (25.0%)

 3 + 

11 (45.8%)

11 (45.8%)

Grade

 I

0 (0.0%)

4 (16.7%)

MCp = 0.141

 II

18 (75.0%)

16 (66.7%)

 III

6 (25.0%)

4 (16.7%)

Stage

   

 IA

4 (16.7%)

6 (25.0%)

MCp = 0.236

 IIA

12 (50.0%)

5 (20.8%)

 IIB

2 (8.3%)

4 (16.7%)

 IIIA

1 (4.2%)

4 (16.7%)

 IIIC

5 (20.8%)

5 (20.8%)

  1. SD standard deviation, BMI body mass index, ER estrogen receptor, PR progesterone receptor, MC Monte Carlo
  2. P P-value for comparing between intermittent fasting and non-fasting
  3. *Statistically significant at P < 0.05